Private Equity: Is Your Value Creation Plan Aimed at the Right Structural Target? Here Is What the EBITDA Is Not Telling You.
Private Equity Segment Paper Three — Website Version — Published June 2026 — Schneider Axiom Institute
Lawrence M. Schneider — Schneider Axiom Institute — Version 1.0 — June 2026
Five questions about the value creation plan currently on your desk — before the 100-day launch:
Every initiative in the plan is aimed at the EBITDA improvement the investment thesis requires. Has any instrument identified the Governing Business Constraint that is governing the EBITDA at the structural level below every initiative — or is the plan improving the EBITDA's expressions rather than resolving the structural cause that will continue governing those expressions through every initiative's execution?
The plan's initiative priority sequence was determined by the EBITDA improvement each initiative is projected to produce. If the Governing Business Constraint is governing the EBITDA at a structural level below the initiative with the highest projected improvement, that initiative will produce activity without EBITDA improvement — because the constraint will continue governing the EBITDA regardless of how precisely the initiative is executed against the symptom. Has the priority sequence been validated against a structural finding?
The management team contributed to the value creation plan's initiative identification. The management team has been operating inside the Governing Business Constraint for the entire period the financial performance has been below its potential. Their initiative recommendations are the best operating intelligence available from inside the constraint's execution environment. They are not a diagnostic finding from outside it. Has the diagnostic that produces the finding from outside the constraint's execution environment been applied before the management team's recommendations were incorporated into the plan?
The add-on acquisition strategy the plan incorporates assumes the platform company's operational infrastructure can absorb the add-on's volume at the margin the combined platform thesis requires. If the platform company has an unidentified Governing Business Constraint, the add-on acquisition will scale the constraint rather than the platform. Has the platform company's Governing Business Constraint been identified before the add-on strategy was incorporated into the value creation plan?
When the value creation plan is presented to the investment committee and the LP base as the specific thesis for this acquisition's return performance, what does the plan's structural foundation say about the diagnostic capability the fund brought to the planning process — and what does the fund's LP base believe about the rigor of that capability?
The value creation plan designed from a Governing Business Constraint finding produces EBITDA improvement at the structural cause level. The value creation plan designed from the EBITDA's expressions produces the activity the investment committee approves and the EBITDA gap the portfolio review explains. At a two-hundred basis point IRR difference per initiative cycle aimed at the wrong structural target — the planning decision is the fund return decision. The diagnostic costs eighty-nine dollars. The plan costs whatever the fund's return multiple applies to the EBITDA gap between the correct structural target and the one the plan is currently aimed at.
The value creation plan is the most consequential document a private equity firm produces for any acquisition — and the one most likely to be aimed at the wrong structural target. Not because the plan is poorly designed. Because the plan is designed from the best available operating intelligence about the EBITDA improvement the thesis requires — and the best available operating intelligence is the quality of earnings findings, the management team's recommendations, and the operational review's gap identification. All three are accurate at the symptom level. None of them produces the Governing Business Constraint finding — the structural identification of the cause governing the EBITDA at the level below every symptom the plan's initiatives are aimed at. I spent fifty years watching operating companies execute value creation plans that were professionally designed, correctly resourced, and precisely aimed at the wrong structural target. The plan improved the symptom. The constraint continued governing the performance the symptom was recording. The improvement did not hold at the EBITDA level the investment thesis required because the improvement was at the symptom level and the constraint was governing the EBITDA at the structural level below it. The diagnostic-first planning standard is the instrument that distinguishes the structural target from the symptomatic one before the plan is launched rather than after the initiatives have produced the activity the investment committee approved without the EBITDA the thesis required. I watched a specific version of this pattern in a PE-backed distribution company whose value creation plan had been built from the management team's operating recommendations — a management team that had been operating inside the Governing Business Constraint for six years before the acquisition and whose recommendations were the most intelligent available from inside the constraint's execution environment. The plan was professionally designed. The initiatives were correctly identified as the EBITDA improvement opportunities the due diligence had supported. Every initiative was aimed at the downstream expressions of a Strategic Constraint in the pricing architecture that the management team had been navigating around for six years — not because they were incapable of identifying it but because they had been inside it long enough that the navigation had become the operating standard rather than the diagnostic signal. Nobody in the room asked what was governing the expressions the initiatives were aimed at. Not the Operating Partner. Not the management team. Not the investment committee. And not me — not at that stage of the methodology's development, when the SAI framework was still being built from fifty years of watching exactly that pattern cost businesses the EBITDA improvement the plans had been designed to produce. The diagnostic-first planning standard that this paper describes is the instrument that room needed before the plan was launched. This paper is the argument for having it in the room next time. — Lawrence M. Schneider, Founder and CEO, Schneider Axiom Institute — Founder of U.S. Lock Corporation, now owned by The Home Depot
Section One — What the Value Creation Plan Is Missing
The Planning Instrument Gap
The value creation plan is built from three primary data sources — the quality of earnings findings, the management team's operating recommendations, and the operational review's gap analysis. All three are excellent sources of information about the EBITDA improvement opportunity and the operational gaps the initiatives should address. None of the three produces the Governing Business Constraint finding — the structural identification of the cause governing the EBITDA at the level below the opportunities and gaps the plan's initiatives are designed around.
The quality of earnings identifies the EBITDA adjustments — the owner adjustments, the one-time items, and the run-rate normalization that produce the investment EBITDA the thesis multiple is applied to. It does not identify the Governing Business Constraint that is suppressing the investment EBITDA below the level the thesis multiple requires the business to reach. The management team's operating recommendations identify the initiatives the management team believes will produce the EBITDA improvement the thesis requires. The management team's recommendations are informed by years of operating inside the Governing Business Constraint's execution environment — which makes the recommendations accurate at the symptom level and structurally limited by the constraint's boundary. The operational review identifies the process gaps, the technology gaps, and the capacity constraints the operational assessment has observed. It does not identify the Governing Business Constraint that is governing the operational performance the gaps are recording.
The diagnostic gap in the value creation plan is the absence of the one instrument that examines the EBITDA at the structural cause level rather than at the performance improvement opportunity level. The SAI Business Constraint Diagnostic is that instrument. Applied before the 100-day plan is finalized, it identifies the Governing Business Constraint that the quality of earnings, the management team recommendations, and the operational review collectively produce the symptoms of without producing the structural finding that the plan's initiatives need to be aimed at.
What the EBITDA Is and Is Not Telling You
The EBITDA is the most precisely measured number in every private equity portfolio company engagement — and the least structurally informative. It measures what the business produces. It does not identify what governs the production. The Governing Business Constraint that is suppressing the EBITDA below the investment thesis's required level is operating at the structural cause level — governing the market performance, the operational output, the organizational execution, or the leadership decision quality that the EBITDA is recording as the financial result of those four structural conditions. The EBITDA records the result. The Governing Business Constraint governs the result. The value creation plan that improves the EBITDA without identifying the Governing Business Constraint is improving the recorded result of the structural cause rather than the structural cause itself — and the improvement does not hold at the level the thesis requires because the Governing Business Constraint continues governing the structural conditions that the EBITDA records.
Section Two — Seven Value Creation Plans and What the Diagnostic Changed
The Plan That Prioritized the Wrong Initiative First
A private equity deal team identified three major value creation opportunities from the due diligence findings — a revenue growth initiative, an operational efficiency program, and an organizational restructuring. The investment committee approved all three. The 100-day plan prioritized them in the order of their projected EBITDA improvement: revenue growth first, operational efficiency second, organizational restructuring third. The revenue growth initiative was executed at the full resource commitment the plan required. The EBITDA improvement at the initiative's completion was eleven percent of the thesis projection.
The Governing Business Constraint — an Organizational Constraint in the authority structure that was preventing the management team from executing the revenue growth strategy at the customer acquisition rate the initiative required — had been governing the revenue performance before the acquisition and continued governing the revenue growth initiative's execution throughout the 100-day plan's implementation. The initiative had been correctly identified as the highest-EBITDA-impact opportunity. It had been incorrectly prioritized ahead of the Organizational Constraint resolution that was the structural prerequisite for the revenue growth initiative to produce the EBITDA the priority ranking had projected. The diagnostic applied before the prioritization decision would have identified the Organizational Constraint as the first-order resolution — the structural prerequisite that every subsequent initiative required before it could produce the EBITDA improvement the plan had ranked it for.
The Plan the Management Team Had Been Waiting For
A private equity Operating Partner applied the SAI diagnostic to a portfolio company as the first post-close conversation with the management team — before the 100-day plan was designed and before the management team's initiative recommendations were solicited. The diagnostic session produced a finding that changed the planning conversation permanently: the management team had been operating inside a Strategic Constraint in the pricing architecture for three years before the acquisition and had been unable to present the pricing restructuring recommendation to the prior ownership because they had lacked the structural framework that would have made the recommendation defensible rather than a preference.
The diagnostic finding gave the management team the structural language for the recommendation they had been unable to make. The CEO's response when the finding was presented: "We have known the pricing architecture was the governing problem for three years. Every time we tried to make the case for restructuring it, the prior ownership asked for the analytical support we did not have the framework to produce. You have just given us the framework." The value creation plan was designed around the Strategic Constraint finding rather than around the management team's prior recommendations — which had been aimed at the operational symptoms the pricing constraint was producing rather than at the pricing architecture itself. The EBITDA improvement in year one following the pricing restructuring exceeded the investment thesis projection by fourteen percent. The management team had been carrying the structural insight for three years. The diagnostic had given it the professional language the ownership relationship required.
The 100-Day Plan the Diagnostic Redesigned
A private equity Operating Partner applied the SAI diagnostic to a portfolio company between the close date and the 100-day plan's finalization — a specific timing decision the Operating Partner had introduced as the diagnostic-first planning standard after the prior two portfolio company value creation plans had produced activity without thesis EBITDA at year one. The diagnostic identified the Governing Business Constraint in the portfolio company's organizational architecture — a Leadership Constraint in the CEO's decision centralization that was governing the management team's execution authority in the three functional areas where the 100-day plan's highest-priority initiatives required the most independent management decision-making.
Three of the six 100-day plan initiatives had been designed around the functional improvements the three decision-centralized areas required. All three were correctly identified as improvement opportunities. All three were structural failures waiting to happen — because the Leadership Constraint was governing the management team's execution authority in precisely the areas the three initiatives required independent decision-making to produce the EBITDA improvements the plan had projected. The diagnostic finding redesigned three of the six initiatives: the Leadership Constraint resolution became the first-order initiative, and the three functional improvements were resequenced as second-order initiatives dependent on the Leadership Constraint's resolution rather than as concurrent initiatives that the unresolved constraint would govern to the same eleven-percent performance level the prior plans had produced. The plan launched redesigned. The EBITDA improvement at the end of the 100-day plan's extended timeline — the Leadership Constraint resolution required sixty additional days — was at ninety-three percent of the thesis projection. The prior two portfolio company plans had not reached sixty percent at comparable timeline points.
The Value Creation Plan That Produced the Fund's Best Exit
A private equity fund introduced the SAI diagnostic-first planning standard across all new portfolio company acquisitions in a specific fund vintage — applied before the 100-day plan was finalized for every acquisition in the portfolio. The fund vintage's portfolio performance at the three-year mark was the highest in the fund's history. The managing partner's attribution at the investor day presentation was specific: the diagnostic-first planning standard had produced value creation plans that were aimed at structural findings rather than at EBITDA expressions — and the plans aimed at structural findings had produced EBITDA improvement at the cause level rather than at the symptom level, which meant the improvement held at the exit valuation rather than compressing between the holding period's EBITDA and the exit buyer's due diligence findings.
The fund vintage's best performing exit was a business services company whose Governing Business Constraint — a Market Constraint in the customer acquisition architecture — had been identified before the 100-day plan was launched and resolved as the first-order value creation initiative. The customer acquisition rate improvement that followed the Market Constraint resolution produced an EBITDA trajectory that the exit buyer's due diligence validated at a multiple that exceeded the investment thesis projection by twenty-two percent. The exit multiple reflected a business whose Governing Business Constraint had been structurally resolved rather than a business whose EBITDA expressions had been improved while the constraint continued governing the structural performance below the expressions. The managing partner's LP letter for the vintage's exit attributed the twenty-two percent premium to the diagnostic-first planning standard. The fund's next fundraise featured the standard as a specific value creation differentiator.
The Add-On That the Diagnostic Made Strategically Coherent
A private equity fund's platform company strategy included an add-on acquisition that the investment thesis required to reach the combined platform EBITDA the exit multiple demanded. The platform company's diagnostic — applied before the add-on acquisition was closed — identified a Governing Business Constraint in the operational infrastructure that the add-on's volume would amplify rather than absorb. The Operating Partner's response to the diagnostic finding was the specific planning decision this paper is designed to enable: the add-on acquisition timeline was extended by four months to allow the platform company's Governing Business Constraint resolution to precede the add-on's volume integration rather than follow it.
The four-month extension cost the fund the add-on's four months of EBITDA contribution — a cost the Operating Partner calculated as significantly lower than the alternative: closing the add-on on the original timeline, amplifying the platform company's Governing Business Constraint to the combined volume level, and managing the operational crisis the amplified constraint would produce at the combined platform scale. The add-on was closed four months later against a resolved platform company. The combined platform's EBITDA at six months post-close was at one hundred and seven percent of the thesis projection. The four-month extension had not been a setback. It had been the specific planning decision that the diagnostic finding had made it possible to make before the add-on amplified the constraint rather than after.
The LP Presentation That Featured the Diagnostic
A private equity fund's managing partner introduced the SAI diagnostic-first planning standard to the fund's LP base at the annual investor meeting as a specific value creation differentiator — presenting the standard as the structural intelligence capability that distinguished the fund's portfolio company planning approach from the market's standard quality of earnings and operational review-based planning process. The LP presentation documented three portfolio companies where the diagnostic-first standard had produced value creation plans aimed at structural findings rather than at EBITDA expressions — and the specific EBITDA improvement rates at year one that the structurally-aimed plans had produced compared to the fund's prior vintage where the diagnostic standard had not been applied.
The LP base's response was specific and commercially consequential: four LPs who had been evaluating re-up commitments for the fund's next vintage increased their commitment levels after the presentation — citing the diagnostic-first planning standard as the specific value creation capability that distinguished the fund's approach from the competing funds they were evaluating simultaneously. The managing partner had not introduced the diagnostic standard as an LP communication strategy. It had been introduced as a portfolio company planning improvement. The LP response to the standard's documentation confirmed what the portfolio company performance data had produced: the diagnostic-first planning standard was not just a portfolio company value creation instrument. It was a fund-level differentiator in the LP relationship — the specific structural intelligence capability that every LP evaluating a fund's value creation thesis would eventually require the fund to demonstrate.
The Exit Conversation That Did Not Require Explanation
A private equity fund's exit process for a portfolio company whose value creation plan had been designed from the Governing Business Constraint finding produced the most commercially productive exit process the fund's managing partner had conducted in twelve years of practice. The difference was specific: the exit buyer's due diligence team arrived at the portfolio company with the standard due diligence instruments — quality of earnings, management assessment, operational review — and found a business whose Governing Business Constraint had been identified, resolved, and documented before the value creation plan had been designed. The due diligence findings were not findings. They were confirmations — the structural documentation of a resolved Governing Business Constraint that the seller's value creation record had already produced as evidence.
The exit conversation did not require the EBITDA gap explanation, the management team defense, or the value creation plan justification that the prior fund vintage's exit processes had required. The buyer's due diligence team asked the questions the standard due diligence process produces. The seller's documentation answered them with the structural clarity that the diagnostic-first planning standard had built into the value creation record from day one. The exit multiple reflected the documented constraint resolution rather than the buyer's risk premium for an unresolved structural limitation. The managing partner's observation at the closing: "For the first time in twelve years, the exit conversation was about what we had built rather than about what we had managed around."
Section Three — The Diagnostic-First Planning Standard
The Planning Decision That Changes Every Subsequent Decision
The value creation plan designed from the Governing Business Constraint finding is the plan that changes every subsequent planning decision in the holding period — the initiative priority sequence, the management team authority structure, the add-on timing, the exit preparation, and the LP communication. The diagnostic finding is not the plan. It is the structural intelligence that makes the plan structurally correct before the first initiative is launched rather than structurally corrected after the first initiative has produced activity without thesis EBITDA.
The diagnostic-first planning standard costs eighty-nine dollars and produces the structural finding before the 100-day plan consumes the operating budget, the management relationship capital, and the holding period time that the wrong structural target would otherwise absorb. The fund that applies the diagnostic before the plan is the fund whose value creation record documents structural resolutions rather than symptomatic improvements — and whose LP base, exit buyers, and investment committee see the difference between the two in the EBITDA trajectory that the structurally-aimed plan produces.
If You Are the Deal Team or Operating Partner
The SAI Certified Axiom Executive credential develops the Governing Business Constraint identification capability at the executive-level diagnostic standard the value creation planning function requires. The credentialed Operating Partner is the Operating Partner whose value creation plans are designed from structural findings rather than from EBITDA expressions — and whose portfolio companies produce the EBITDA improvement the investment thesis requires rather than the activity the value creation plan describes.
Learn About the Certified Axiom Executive (CAE) →
Learn About the Certified Axiom Strategist (CAS) →
Take the $89 Business Constraint Diagnostic →
Schedule Coffee with Larry — Free. 15 Minutes. No Agenda. →
The Axiom Leaders Circle — Value Creation Intelligence at Fund Level
The private equity professional who joins The Axiom Leaders Circle — Where Constraint Leaders Come to Grow, Contribute, Solve, and Be Recognized — enters the professional community whose documented Governing Business Constraint findings give every fund's value creation team the structural intelligence that the fund's own portfolio transaction history cannot generate alone. The Circle member who documented a Leadership Constraint resolution in a business services portfolio company has given every PE Operating Partner in the Circle the specific resolution architecture that the portfolio company's 100-day plan required — before the Operating Partner's portfolio company requires it. The Circle's cross-industry knowledge base is the value creation intelligence library that no PE industry association, operating partner network, or fund-level knowledge management system currently provides. It compounds with every member's contribution. It is free to join.
Learn About The Axiom Leaders Circle →
Join The Axiom Leaders Circle — Free →
Read the Complete SAI Private Equity Series
Paper One — Is the Governing Business Constraint Visible in Your Due Diligence? →
Paper Two — Is the Portfolio Company Hitting Its Targets? →
Author: Lawrence M. Schneider, Founder and CEO, Schneider Axiom Institute | Published June 2026 — Version 1.0 | Private Equity Segment Paper Three of Three
Lawrence M. Schneider served as founder, CEO, and Chairman of the Board of U.S. Lock Corporation, now owned by The Home Depot. He brings fifty years of CEO-level operating experience across manufacturing, distribution, construction, and franchising. He is the founder and CEO of the Schneider Axiom Institute, the developer of the Seven Classes of Business Constraint methodology, and the author of the 21-volume SAI eBizBooks Series.
© 2026 Schneider Axiom Institute LLC. All Rights Reserved. The Seven Classes of Business Constraint methodology, the Governing Business Constraint identification capability, the SAI Business Constraint Diagnostic, and all credential marks — Foundational Diagnostic Credential (FDC), Certified Axiom Strategist (CAS), and Certified Axiom Executive (CAE) — are trademarks and proprietary intellectual property of Schneider Axiom Institute LLC.
"Before you can solve the problem, you must identify the Governing Business Constraint." — Lawrence M. Schneider, Founder, Schneider Axiom Institute
Strengthen the Individual.
Strengthen the Family.
Strengthen the Company.
Strengthen America.